Antibody-cytokine engrafted proteins and methods of use for immune related disorders

Patent metadata

Field	Value
Publication number	US-11930837-B2
Application number	US-202117403710-A
Country	US
Kind code	B2
Filing date	Aug 16, 2021
Priority date	May 24, 2017
Publication date	Mar 19, 2024
Grant date	Mar 19, 2024

Abstract

The present disclosure provides antibody cytokine engrafted proteins that bind to and stimulate intracellular signaling through a high affinity interleukin receptor. The antibody cytokine engrafted proteins find use in enhancing anti-inflammatory cell responses, and reducing pro-inflammatory effects in the treatment, amelioration and prevention of immune related disorders such as Type 1 Diabetes.

First claim

What is claimed is:

1. A method of expanding Treg cells in a patient in need thereof, comprising administering an antibody cytokine engrafted protein comprising:
(a) a heavy chain variable region (VH) that comprises a HCDR1 of SEQ ID NO: 17, a HCDR2 of SEQ ID NO: 18, a HCDR3 of SEQ ID NO: 19; and
(b) light chain variable region (VL) that comprises a LCDR1 of SEQ ID NO: 30, a LCDR2 of SEQ ID NO: 31, and a LCDR3 of SEQ ID NO: 32; and
wherein the HDCR1 comprises an Interleukin 2 (IL2) molecule.

2. The method of claim 1 , wherein the Treg cells are expanded and CD8 T effector cells are not expanded.

3. The method of claim 1 , wherein the Treg cells are expanded and NK cells are not expanded.

4. The method of claim 1 , wherein the patient has an immune related disorder.

5. The method of claim 4 , wherein the immune related disorder is selected from the group consisting of: Type 1 diabetes, System Lupus Erythematosus, Vitiligo, chronic graft versus host disease (cGvHD), acute graft versus host disease, HIV-induced vasculitis, Alopecia areata, Systemic sclerosis morphoea, and primary anti-phospholipid syndrome.

6. The method of claim 1 , wherein the antibody cytokine engrafted protein is administered in combination with another therapeutic agent.

7. The method of claim 6 , wherein the therapeutic agent is another antibody cytokine engrafted protein.

Assignees

• Novartis Ag

Inventors

• Diaz-De-Durana Yaiza
• Didonato Michael
• Filippi Christophe
• Meeusen Shelly
• Spraggon Glen

Classifications

• C07K16/11 Primary

  Paramyxoviridae (F); Pneumoviridae (F), e.g. respiratory syncytial virus [RSV] · CPC title

• A23L7/197 Primary

  Treatment of whole grains not provided for in groups A23L7/117 - A23L7/196 (preservation A23B9/00) · CPC title

• A23L7/104

  Fermentation of farinaceous cereal or cereal material; Addition of enzymes or microorganisms · CPC title

• A61K38/2013

  IL-2 · CPC title

• B02B1/04

  Wet treatment, e.g. washing, wetting, softening · CPC title